US Stocks
Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc








Key Stats

Today Low/High
4.92 / 4.92
52 Week Low/High
$3.56 / $9.45
Market Cap

Company Details

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration ('FDA') of ONIVYDE® for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack's agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE® clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019. The Company is seeking potential acquirers for its remaining preclinical assets.
Merrimack Pharmaceuticals Inc
Health Technology

Discover more

Frequently Asked Questions

What is Merrimack Pharmaceuticals Inc share price today

Can Indians buy Merrimack Pharmaceuticals Inc shares?

How can I buy Merrimack Pharmaceuticals Inc shares from India?

Can Fractional shares of Merrimack Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Merrimack Pharmaceuticals Inc stocks?

We are a SEBI registered investement advisor